Skip to main content
Top
Published in: BMC Geriatrics 1/2022

01-12-2022 | Alzheimer's Disease | Research

Factors associated with change over time in quality of life of people with dementia: longitudinal analyses from the MODEM cohort study

Authors: Derek King, Nicolas Farina, Clare Burgon, Yvonne Feeney, Sharne Berwald, Elizabeth Bustard, Laura Gallaher, Ruth Habibi, Raphael Wittenberg, Adelina Comas-Herrera, Martin Knapp, Sube Banerjee

Published in: BMC Geriatrics | Issue 1/2022

Login to get access

Abstract

Background

Research to date offers mixed evidence about the relationship between quality of life and severity of cognitive impairment in people with dementia. We aimed to investigate longitudinal changes in patient- and proxy-rated health-related quality of life (HRQL) by severity of dementia and explore factors associated with changes in HRQL over a one-year period. We used data from the MODEM longitudinal cohort study which recruited dyads of persons with clinically diagnosed dementia and their principal carer and interviewed them face-to-face at baseline and again 1 year later.

Methods

Quota sampling was used to generate balanced numbers (target n = 100 for each severity level) of people with mild cognitive impairment (20+ on the standardised Mini-Mental State Examination (sMMSE)), moderate cognitive impairment (score 10 to 19), and severe cognitive impairment (score 0 to 9). Persons with dementia without an identifiable family carer or other informant (e.g., a formal/professional/paid carer) were excluded from the study. Participants answered a series of questions measuring their HRQL: DEMQOL, DEMQOL-proxy, EQ-5D-3 L, EQ-5D-3L proxy. Multiple regression models were built to understand the effects of baseline demographics and dementia symptoms (cognitive impairment, neuropsychiatric symptoms) on change in HRQL over 1 year.

Results

Two hundred and forty-three dyads of people with clinically diagnosed dementia and carers completed baseline and follow-up interviews. Most measures of HRQL remaining relatively stable between time-points, but one index of HRQL, EQ-5D proxy, significantly declined. Depending on the HRQL measure, different factors were associated with change in HRQL. The only factor consistently associated with decline in HRQL (when compared to improvement) was having a diagnosis of a non-Alzheimer’s dementia.

Conclusions

Deterioration in HRQL is not an inevitable part of the dementia journey. However, people with non-Alzheimer’s dementias may be more susceptible to HRQL decline. This may indicate that those with non-Alzheimer’s dementia may benefit from specific support focussed on maintaining their quality of life.
Literature
3.
go back to reference Todd S, Barr S, Roberts M, Passmore AP. Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry. 2013;28(11):1109–24.PubMed Todd S, Barr S, Roberts M, Passmore AP. Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry. 2013;28(11):1109–24.PubMed
4.
go back to reference Kurrle S, Brodaty H, Hogarth R. Physical comorbidities of dementia. Cambridge: Cambridge University Press; 2012.CrossRef Kurrle S, Brodaty H, Hogarth R. Physical comorbidities of dementia. Cambridge: Cambridge University Press; 2012.CrossRef
5.
go back to reference Banerjee S, Samsi K, Petrie CD, Alvir J, Treglia M, Schwam EM, et al. What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia. Int J Geriatr Psychiatry. 2009;24(1):15–24. https://doi.org/10.1002/gps.2090.CrossRefPubMed Banerjee S, Samsi K, Petrie CD, Alvir J, Treglia M, Schwam EM, et al. What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia. Int J Geriatr Psychiatry. 2009;24(1):15–24. https://​doi.​org/​10.​1002/​gps.​2090.CrossRefPubMed
17.
go back to reference Molloy DW, Alemayehu E, Roberts R. Reliability of a standardized Mini-mental state examination compared with the traditional Mini-mental state examination. Am J Psychiatry. 1991;148(1):102–5.CrossRef Molloy DW, Alemayehu E, Roberts R. Reliability of a standardized Mini-mental state examination compared with the traditional Mini-mental state examination. Am J Psychiatry. 1991;148(1):102–5.CrossRef
19.
go back to reference Centers for Disease Control and Prevention. Measuring healthy days: population assessment of health-related quality of life. Atlanta: CDC; 2000. Centers for Disease Control and Prevention. Measuring healthy days: population assessment of health-related quality of life. Atlanta: CDC; 2000.
20.
go back to reference Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, et al. Measurement of health-related quality of life for people with dementia: Development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess. 2005;9(10):1–93 iii–iv.CrossRef Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, et al. Measurement of health-related quality of life for people with dementia: Development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess. 2005;9(10):1–93 iii–iv.CrossRef
21.
go back to reference EuroQol Group. EuroQol—A new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRef EuroQol Group. EuroQol—A new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRef
22.
go back to reference Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–108.CrossRef Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–108.CrossRef
24.
go back to reference Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14.CrossRef Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14.CrossRef
26.
go back to reference Goldberg D, Williams P. General health questionnaire (GHQ). Swindon: NferNelson; 2000. Goldberg D, Williams P. General health questionnaire (GHQ). Swindon: NferNelson; 2000.
27.
go back to reference Ware JE Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33.CrossRef Ware JE Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33.CrossRef
29.
go back to reference Van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16(3):219–42.CrossRef Van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16(3):219–42.CrossRef
31.
go back to reference Allison PD. Change scores as dependent variables in regression analysis. Sociol Methodol. 1990;20:93–114.CrossRef Allison PD. Change scores as dependent variables in regression analysis. Sociol Methodol. 1990;20:93–114.CrossRef
32.
go back to reference Coretti S, Ruggeri M, McNamee P. The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev Pharmacoecon Outcomes Res. 2014;14:221–33.CrossRef Coretti S, Ruggeri M, McNamee P. The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev Pharmacoecon Outcomes Res. 2014;14:221–33.CrossRef
33.
go back to reference Luo N, Johnson JA, Coons SJ. Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med Care. 2010;48(4):365–71.CrossRef Luo N, Johnson JA, Coons SJ. Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med Care. 2010;48(4):365–71.CrossRef
34.
go back to reference StataCorp LP. Stata/SE 14.2 for windows [64-bit x86–64]. College Station: StataCorp LP; 2015. StataCorp LP. Stata/SE 14.2 for windows [64-bit x86–64]. College Station: StataCorp LP; 2015.
35.
go back to reference Wittenberg R, Knapp M, Hu B, Comas-Herrera A, King D, Rehill A, et al. The cost of dementia in England. Int J Geriatr Psychiatry. 2019;34:1095–103.CrossRef Wittenberg R, Knapp M, Hu B, Comas-Herrera A, King D, Rehill A, et al. The cost of dementia in England. Int J Geriatr Psychiatry. 2019;34:1095–103.CrossRef
38.
go back to reference Trigg R, Jones RW, Knapp M, King D, Lacey LA. The relationship between changes in quality of life outcomes and progression of Alzheimer’s disease: results from the dependence in AD in England 2 longitudinal study. Int J Geriatr Psychiatry. 2015;30(4):400–8. https://doi.org/10.1002/gps.4150.CrossRefPubMed Trigg R, Jones RW, Knapp M, King D, Lacey LA. The relationship between changes in quality of life outcomes and progression of Alzheimer’s disease: results from the dependence in AD in England 2 longitudinal study. Int J Geriatr Psychiatry. 2015;30(4):400–8. https://​doi.​org/​10.​1002/​gps.​4150.CrossRefPubMed
39.
go back to reference Laybourne A, Livingston G, Cousins S, Rapaport P, Lambe K, Frenais FL, et al. Carer coping and resident agitation as predictors of quality of life in care home residents living with dementia: managing agitation and raising quality of life (MARQUE) English national care home prospective cohort study. Int J Geriatr Psychiatry. 2019;34(1):106–13. https://doi.org/10.1002/gps.4994.CrossRefPubMed Laybourne A, Livingston G, Cousins S, Rapaport P, Lambe K, Frenais FL, et al. Carer coping and resident agitation as predictors of quality of life in care home residents living with dementia: managing agitation and raising quality of life (MARQUE) English national care home prospective cohort study. Int J Geriatr Psychiatry. 2019;34(1):106–13. https://​doi.​org/​10.​1002/​gps.​4994.CrossRefPubMed
40.
go back to reference Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56(5):395–407.CrossRef Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56(5):395–407.CrossRef
46.
go back to reference Wu Y-T, Clare L, Hindle JV, Nelis SM, Martyr A, Matthews FE. Dementia subtype and living well: results from the improving the experience of dementia and enhancing active life (IDEAL) study. BMC Med. 2018;16(1):140.CrossRef Wu Y-T, Clare L, Hindle JV, Nelis SM, Martyr A, Matthews FE. Dementia subtype and living well: results from the improving the experience of dementia and enhancing active life (IDEAL) study. BMC Med. 2018;16(1):140.CrossRef
Metadata
Title
Factors associated with change over time in quality of life of people with dementia: longitudinal analyses from the MODEM cohort study
Authors
Derek King
Nicolas Farina
Clare Burgon
Yvonne Feeney
Sharne Berwald
Elizabeth Bustard
Laura Gallaher
Ruth Habibi
Raphael Wittenberg
Adelina Comas-Herrera
Martin Knapp
Sube Banerjee
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2022
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-022-03142-z

Other articles of this Issue 1/2022

BMC Geriatrics 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine